BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Journal for ImmunoTherapy of Cancer / Sep 22, 2022
Poster Presentation With Sanofi presenting Pre-Clinical Translational Data of SAR444881 (BND-22)
ASCO 2022 Annual Meeting
BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models
Poster Presentations at AACR 2020 Virtual Annual Meeting